IP Library Granted Patent US 8,445,450
Granted Patent B2
US 8,445,450 · App. 13/438,905 · Granted May 21, 2013

Antithrombotic dual inhibitors comprising a biotin residue

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,445,450
App. No.
13/438,905
Granted
May 21, 2013
Kind
B2
Abstract

The present invention relates compounds of the formula (I) oligosaccharide-spacer-A  (I), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising two to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-III mediated) anti-Xa activity per se; the spacer is an essentially pharmacologically inactive flexible linking residue having a chain length of 10 to 70 atoms; A is the residue —CH[NH—SO 2 —R 1 ][CO—NR 2 —CH(4-benzamidine)-CO—NR 3 R 4 ].

Claims (21)

1. A method for treating thrombosis in a subject in need of such treatment, the method comprising administering to the subject an effective amount of an antithrombotic compound of the formula (I)

oligosaccharide-spacer-A  (I),

wherein the oligosaccharide is a negatively charged pentasaccharide of the formula (II)

wherein R 5 is OSO 3 − or (1-8C)alkoxy, the charge being compensated by positively charged couriterions;

the spacer is

A is the residue —CH[NH—SO 2 —R 1 ][CO—NR 2 —CH(4-benzamidine)-CO—NR 3 R 4 ],

wherein R 1 is phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, (iso)quinolinyl, tetrahydro(iso)quinolinyl, 3,4-dihydro-1H-isoquinolinyl, chromanyl or the camphor group, which groups may optionally be substituted with one or more substituents selected from (1-8C)alkyl or (1-8C)alkoxy; and wherein R 2 and R 3 are independently H or (1-8C)alkyl; R 4 is (1-8C)alkyl or (3-8C)cycloalkyl; or R 3 and R 4 together with the nitrogen atom to which they are bonded are a nonaromatic (4-8) membered ring optionally containing another heteroatom, the ring optionally being substituted with (1-8C)alkyl or SO 2 -(1-8C)alkyl;

or a pharmaceutically acceptable salt thereof;

wherein the spacer of the compound of formula I comprises at least one covalent bond with a biotin residue or an analogue of the formula —(CH 2 ) 4 —NR-BT, where BT is the residue

where R is H or (1-4C)alkyl,

and neutralizing the anti-thrombotic ac of the compound by administering avidin or streptavidin.

2. The method of claim 1 , wherein the pentasaccharide residue has the structure

wherein R 5 is OCH 3 or OSO 3 − .

3. The method of claim 2 , wherein the pentasaccharide residue has the structure

4. The method of claim 1 , wherein R 1 is phenyl or naphthyl, optionally substituted with one or more substituents selected from methyl or methoxy.

5. The method of claim 4 , wherein R 1 is 4-methoxy-2,3,6-trimethylphenyl.

6. The method of claim 1 , wherein NR 3 R 4 represents the piperidinyl group.

7. The method of claim 1 , wherein R 2 is H.

8. The method of claim 1 , where the compound is

or a pharmaceutically acceptable salt thereof.

9. The method of claim 8 , where the compound is in the form of a sodium salt.

Assignments (2)
MERGER Recorded Mar 8, 2013
From: ORGANON BIOSCIENCES NEDERLAND B.V.
To: MERCK SHARP & DOHME B.V.
Reel/Frame 029940/0296 →
MERGER Recorded Mar 7, 2013
From: MSD OSS B.V.
To: ORGANON BIOSCIENCES NEDERLAND B.V.
Reel/Frame 029939/0001 →